Zenas BioPharma, Inc. Common Stock

NASDAQ ZBIO
$20.51 3.53 20.79%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 27.5 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
330.23M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
134.58M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
41.80M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
150.43 %

Upcoming events Zenas BioPharma, Inc. Common Stock

All events
No upcoming events scheduled

Stock chart Zenas BioPharma, Inc. Common Stock

Stock analysis Zenas BioPharma, Inc. Common Stock

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-2.03 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
0.35 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.83 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.20 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-57.25 -50.00

Price change Zenas BioPharma, Inc. Common Stock per year

6.43$ 25.68$
Min Max

Summary analysis Zenas BioPharma, Inc. Common Stock

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Zenas BioPharma, Inc. Common Stock

Revenue and net income Zenas BioPharma, Inc. Common Stock

All parameters

About company Zenas BioPharma, Inc. Common Stock

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and Fc"RIIb for the treatment of several I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Address:
852 Winter Street, Waltham, MA, United States, 02451
Company name: Zenas BioPharma, Inc. Common Stock
Issuer ticker: ZBIO
ISIN: US98937L1052
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2024-09-13
Sector: Healthcare
Industry: Biotechnology
Site: https://zenasbio.com